Canada's drug safety approach needs to change, says report
This article was originally published in Scrip
Executive Summary
The priorities of Health Canada are skewed in favour of rapid approvals of new drugs at the expense of assessing them for safety after they reach the market, claims a new report from the Canadian Centre for Policy Alternatives, a charity that advocates social and economic justice.